Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
about
Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitisAntiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitisHerpes simplex epithelial and stromal keratitis: an epidemiologic updateGanciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applicationsEffect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertensionIncidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxisThe Current State of Vaccine Development for Ocular HSV-1 InfectionProspects for developing an effective vaccine against ocular herpes simplex virus infection.Economic evaluation for ophthalmologists.Acute Herpetic Keratitis: What is the Role for Ganciclovir Ophthalmic Gel?Pharmacologic strategies in the prevention and treatment of corneal transplant rejection.Clinical efficacy of oral and topical acyclovir in herpes simplex virus stromal necrotizing keratitis.Exploiting herpes simplex virus entry for novel therapeutics.An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases.An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes.Novel approaches in fighting herpes simplex virus infectionsHerpes simplex keratitis: challenges in diagnosis and clinical management.Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases.The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.Topical ganciclovir in the treatment of acute herpetic keratitis.Practice patterns for herpes simplex keratitis: A survey of ophthalmologists in Gulf Coast countries.Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.Mediators and mechanisms of herpes simplex virus entry into ocular cellsSpecific antibody production in herpes keratitis: intraocular inflammation and corneal neovascularisation as predicting factors.An M2 Rather than a TH2 Response Contributes to Better Protection against Latency Reactivation following Ocular Infection of Naive Mice with a Recombinant Herpes Simplex Virus 1 Expressing Murine Interleukin-4.
P2860
Q24186663-FFD42E27-E0AC-4445-85D5-E1AFF62B5F6EQ24235637-03389E23-DE3B-446B-8973-E379CAC51AA9Q26853504-35E6BC5F-A8C2-4F9F-B366-4CC90E81A195Q27026675-FF88826F-955B-4D1B-B7E5-C2486E3A58C8Q33566458-B9C3FD70-189E-4FE6-85B4-E4B2710EE55EQ35012576-40B5CEA6-B8A6-46C4-9329-1B467D0712F4Q35606611-C3165791-A1AF-4673-B143-60D6F8DC13F3Q36311038-67110A28-643A-4C50-AF61-CC1B36E1DC4FQ36684527-580DA13C-EA2C-419D-8A3E-2428E5C23781Q36748051-A68E30CA-18F5-463E-A8B5-4C4A4717F77BQ36883697-A6BC592D-8176-4481-A0B0-A8D0295EEF4BQ36991715-CF58D73E-51D5-4A59-B5A9-2A94CAC531F9Q37030702-7CA74BB8-DE96-4FE6-89F0-22FF328D0D72Q37146174-E08A847F-4C23-4809-885A-F874210E91A2Q37208892-A65B456E-6ECF-47FC-97CF-4BBB1AC407C1Q37247305-3E5477E0-9202-4CA3-B897-2D88D7B11851Q37316071-D233A617-D84B-4CD5-9400-3EAD0908FF50Q37603658-8122450E-3AE1-4F25-B1C9-1D9814BFACA7Q38303228-A52ECA17-6A5F-4A15-B4A5-482110D4231AQ38650844-7E860888-BB89-4140-81B1-6F3E76A39EEFQ39840108-B9E06A70-25B9-46E4-9123-3F6371AAAECFQ41882382-8EA6C19B-08B3-4FA3-A521-D418B58B243FQ42280324-8D670B70-254E-4965-B9FF-ED207955C6FFQ42734731-54396557-3994-4B05-B9C6-03BD0F58899FQ43881072-E781D372-312E-498D-8935-5B13601189C0Q54264680-E4809BCF-DAE4-4E24-AA94-BAD41F7B6643
P2860
Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
@en
Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
@nl
type
label
Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
@en
Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
@nl
prefLabel
Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
@en
Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
@nl
P2093
P1433
P1476
Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis.
@en
P2093
Charles E Begley
David R Lairson
Kirk R Wilhelmus
Thomas F Reynolds
P304
P356
10.1001/ARCHOPHT.121.1.108
P407
P577
2003-01-01T00:00:00Z